{"id":"NCT01755156","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","officialTitle":"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-11","primaryCompletion":"2016-03-16","completion":"2016-03-16","firstPosted":"2012-12-24","resultsPosted":"2017-03-20","lastUpdate":"2018-09-10"},"enrollment":402,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Omarigliptin","otherNames":["MK-3102"]},{"type":"DRUG","name":"Matching placebo to omarigliptin","otherNames":[]},{"type":"DRUG","name":"Glimepiride","otherNames":["Amaryl®"]},{"type":"DRUG","name":"Matching placebo to glimepiride","otherNames":[]},{"type":"DRUG","name":"Insulin glargine","otherNames":["Lantus"]},{"type":"DRUG","name":"Metformin","otherNames":["Fortamet®","Glucophage®","Glucophage® XR","Glumetza®","Riomet®","Metgluco®","Glycoran®"]}],"arms":[{"label":"Omarigliptin (Phase A) → Omarigliptin (Phase B)","type":"EXPERIMENTAL"},{"label":"Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of omarigliptin compared to placebo in participants with inadequate glycemic control on metformin monotherapy. The primary hypothesis is that after 24 weeks, the addition of treatment with omarigliptin provides greater reduction in hemoglobin A1c (A1C) than placebo.","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A)","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Omarigliptin (Phase A)","deltaMin":-0.54,"sd":null},{"arm":"Placebo to Omarigliptin (Phase A)","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28547998"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":201},"commonTop":["Hypoglycaemia","Blood glucose increased","Headache","Nasopharyngitis","Arthralgia"]}}